Understanding how CRAT contributes to treatment resistance in aggressive breast cancer
Investigating the role of CRAT as a driver of triple negative breast cancer chemoresistance
This study is looking at how a gene called CRAT might help triple negative breast cancer cells survive chemotherapy by boosting their energy, and the goal is to find new ways to treat this tough type of cancer better for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10873780 on NIH RePORTER |
What this research studies
This research investigates the role of the CRAT gene in triple negative breast cancer (TNBC), a type of breast cancer known for its aggressive nature and limited treatment options. The study focuses on how CRAT may help cancer cells resist chemotherapy by enhancing their energy production through a process called mitochondrial oxidative phosphorylation. By examining the mechanisms behind this resistance, the research aims to identify potential new therapeutic targets that could improve treatment outcomes for patients with TNBC. Patients may benefit from insights gained that could lead to more effective treatments in the future.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are undergoing or have undergone neoadjuvant chemotherapy.
Not a fit: Patients with other subtypes of breast cancer or those who have not received chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for overcoming chemotherapy resistance in triple negative breast cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach may yield valuable insights.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Pendleton, Katherine Ellen — Baylor College of Medicine
- Study coordinator: Pendleton, Katherine Ellen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.